---
title: "Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294823747.md"
description: "Fort Lee, New Jersey - August 4, 2026 - Nuvectis Pharma, Inc. (NVCT), a biopharmaceutical company concentrating on novel therapies for complement-related ailments and oncology, disclosed its financial outcomes for Q2 2026. The company also shared recent business advancements."
datetime: "2026-08-04T12:05:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294823747.md)
  - [en](https://longbridge.com/en/news/294823747.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294823747.md)
generator: "portal-rs"
---

# Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Fort Lee, New Jersey - August 4, 2026 - Nuvectis Pharma, Inc. (NVCT), a biopharmaceutical company concentrating on novel therapies for complement-related ailments and oncology, disclosed its financial outcomes for Q2 2026. The company also shared recent business advancements.

### Related Stocks

- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)

## Related News & Research

- [Nuvectis Pharma to present at H.C. Wainwright annual investment conference](https://longbridge.com/en/news/297909736.md)
- [Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT)](https://longbridge.com/en/news/297912026.md)
- [Coya Therapeutics posts September 2026 investor presentation on neurodegeneration pipeline](https://longbridge.com/en/news/297669200.md)
- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**